{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:17:06Z","timestamp":1793477826201,"version":"4.5.0"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.canlet.2019.11.039","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T13:04:19Z","timestamp":1575551059000},"page":"88-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":408,"special_numbering":"C","title":["Human papillomavirus vaccine against cervical cancer: Opportunity and challenge"],"prefix":"10.1016","volume":"471","author":[{"given":"Renjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.11.039_bib2","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines - a review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","article-title":"Current understanding of the mechanism of HPV infection","volume":"118","author":"Schiller","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J. Nat. Cancer. Inst."},{"key":"10.1016\/j.canlet.2019.11.039_bib8","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","article-title":"Beyond cervical cancer: burden of other HPV-related cancers among men and women","volume":"46","author":"Chaturvedi","year":"2010","journal-title":"J. Adolesc. Health"},{"issue":"Suppl 5","key":"10.1016\/j.canlet.2019.11.039_bib9","doi-asserted-by":"crossref","first-page":"F168","DOI":"10.1016\/j.vaccine.2012.06.045","article-title":"Human papillomavirus, human immunodeficiency virus and immunosuppression","volume":"30","author":"Denny","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib10","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.3389\/fmicb.2018.02896","article-title":"Involvement of human papillomaviruses in cervical cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.canlet.2019.11.039_bib11","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.canlet.2019.11.039_bib12","first-page":"59","article-title":"Therapeutic HPV vaccines, Best practice & research","volume":"47","author":"Hancock","year":"2018","journal-title":"Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.canlet.2019.11.039_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2019.11.039_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-based human papillomavirus (HPV) vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1099\/jgv.0.001105","article-title":"ICTV virus Taxonomy profile: Papillomaviridae","volume":"99","author":"Van Doorslaer","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"de Villiers","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2018.04.003","article-title":"Towards quality and order in human papillomavirus research","volume":"519","author":"Muhr","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2018.04.017","article-title":"Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types","volume":"520","author":"Brancaccio","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virusres.2016.11.013","article-title":"The biology of beta human papillomaviruses","volume":"231","author":"Tommasino","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.radonc.2013.06.004","article-title":"Human papillomaviruses and cancer","volume":"108","author":"Haedicke","year":"2013","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib22","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.canlet.2019.11.039_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4424","article-title":"Are 20 human papillomavirus types causing cervical cancer?","volume":"234","author":"Arbyn","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2019.11.039_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1743-422X-10-137","article-title":"Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata","volume":"10","author":"Hawkins","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.canlet.2019.11.039_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/CMR.00013-15","article-title":"Human papillomavirus laboratory testing: the changing paradigm","volume":"29","author":"Burd","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.canlet.2019.11.039_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/path.4533","article-title":"Carcinogenic HPV infection in the cervical squamo-columnar junction","volume":"236","author":"Mirkovic","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2019.11.039_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2741\/2664","article-title":"Structure and function of the papillomavirus E6 protein and its interacting proteins","volume":"13","author":"Liu","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.canlet.2019.11.039_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.11.039_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenviron."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2019.11.039_bib31","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.vaccine.2008.10.085","article-title":"Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence","volume":"27","author":"Bonanni","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"10.1016\/j.canlet.2019.11.039_bib32","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the natural history of human papillomavirus and anogenital cancers","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","article-title":"HPV vaccine cross-protection: highlights on additional clinical benefit","volume":"130","author":"De Vincenzo","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib34","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.4049\/jimmunol.1002756","article-title":"Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium","volume":"185","author":"Trimble","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib35","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib36","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1172\/JCI57149","article-title":"The known unknowns of HPV natural history","volume":"121","author":"Gravitt","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2019.11.039_bib37","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1073\/pnas.92.5.1654","article-title":"Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis","volume":"92","author":"Jeon","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.11.039_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.canlet.2019.11.039_bib39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5306\/wjco.v5.i4.753","article-title":"Role of IL-10 and TGF-beta1 in local immunosuppression in HPV-associated cervical neoplasia","volume":"5","author":"Torres-Poveda","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.039_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.virol.2013.05.038","article-title":"The papillomavirus major capsid protein L1","volume":"445","author":"Buck","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib42","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1128\/JVI.00724-06","article-title":"Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells","volume":"80","author":"Culp","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib43","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"Richards","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.11.039_bib44","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/fmb.09.86","article-title":"The role of furin in papillomavirus infection","volume":"4","author":"Day","year":"2009","journal-title":"Future Microbiol."},{"key":"10.1016\/j.canlet.2019.11.039_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.10.015","article-title":"Cruising the cellular highways: how human papillomavirus travels from the surface to the nucleus","volume":"231","author":"DiGiuseppe","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib46","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1128\/JVI.03222-12","article-title":"Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection","volume":"87","author":"Day","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib47","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1073\/pnas.1302164110","article-title":"Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus","volume":"110","author":"Lipovsky","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.11.039_bib48","doi-asserted-by":"crossref","first-page":"14252","DOI":"10.1073\/pnas.0404229101","article-title":"Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression","volume":"101","author":"Day","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.11.039_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12708","article-title":"Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytes","volume":"19","author":"Bienkowska-Haba","year":"2017","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.canlet.2019.11.039_bib50","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.1038\/sj.onc.1204860","article-title":"Biological activities and molecular targets of the human papillomavirus E7 oncoprotein","volume":"20","author":"Munger","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.11.039_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2019.11.039_bib52","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/j.1349-7006.2007.00546.x","article-title":"Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins","volume":"98","author":"Narisawa-Saito","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2019.11.039_bib53","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1128\/JVI.06243-11","article-title":"High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors","volume":"86","author":"Wetherill","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13046-017-0541-1","article-title":"hrHPV E5 oncoprotein: immune evasion and related immunotherapies","volume":"36","author":"de Freitas","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib55","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1038\/sj.onc.1210916","article-title":"Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression","volume":"27","author":"Kivi","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.11.039_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/path.1490","article-title":"Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16\/18 and numerical chromosome abnormalities","volume":"202","author":"Hopman","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2019.11.039_bib57","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1016\/j.vaccine.2011.09.115","article-title":"Cervical adenocarcinoma: moving towards better prevention","volume":"29","author":"Seoud","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib58","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/ijc.29651","article-title":"Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: results from a European multinational epidemiological study","volume":"137","author":"Holl","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib59","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.5858\/arpa.2016-0356-RA","article-title":"Cervical adenocarcinoma: diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors","volume":"141","author":"Pirog","year":"2017","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib60","first-page":"107","article-title":"HPV negative cervical cancers and primary HPV screening","volume":"10","author":"Tjalma","year":"2018","journal-title":"Facts Views Vis. Obgyn."},{"key":"10.1016\/j.canlet.2019.11.039_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(14)70073-7","article-title":"Filling a gap in cervical cancer screening programmes","volume":"15","author":"Wentzensen","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib62","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2019.11.039_bib63","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib64","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine","volume":"6","author":"Schwarz","year":"2010","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib65","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjc.6602679","article-title":"T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia","volume":"93","author":"Steele","year":"2005","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2019.11.039_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00262-011-1092-5","article-title":"CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend","volume":"61","author":"Kim","year":"2012","journal-title":"Cancer Immunol. Immunother.(CII)"},{"key":"10.1016\/j.canlet.2019.11.039_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijc.24804","article-title":"A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses","volume":"126","author":"Woo","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2005.11.039","article-title":"Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix","volume":"102","author":"Monnier-Benoit","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.coi.2010.12.010","article-title":"Therapeutic vaccination against human papilloma virus induced malignancies","volume":"23","author":"van der Burg","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib70","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/erv.13.23","article-title":"Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer","volume":"12","author":"Morrow","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.canlet.2019.11.039_bib71","author":"Gardasil"},{"key":"10.1016\/j.canlet.2019.11.039_bib72","author":"Gardasil"},{"key":"10.1016\/j.canlet.2019.11.039_bib73","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14712598.7.3.391","article-title":"Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer","volume":"7","author":"Crosbie","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib74","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: Cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib75","author":"Cervarix"},{"key":"10.1016\/j.canlet.2019.11.039_bib76","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.11.039_bib77","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.canlet.2019.11.039_bib78","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18","volume":"321","author":"Pastrana","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib80","first-page":"108","article-title":"Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay","volume":"10","author":"Opalka","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib81","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jnci\/86.7.494","article-title":"A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16","volume":"86","author":"Kirnbauer","year":"1994","journal-title":"J. Nat. Cancer. Inst."},{"key":"10.1016\/j.canlet.2019.11.039_bib82","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper","volume":"92","year":"2017","journal-title":"Releve Epidemiologique Hebd."},{"key":"10.1016\/j.canlet.2019.11.039_bib83","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.canlet.2019.11.039_bib84","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2019.11.039_bib85","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nygard","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib86","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine","volume":"35","author":"Guevara","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib87","first-page":"119","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer, Nature reviews","volume":"13","author":"Bosch","year":"2016","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib88","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 Years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.canlet.2019.11.039_bib89","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib90","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.11.039_bib91","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib93","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.canlet.2019.11.039_bib94","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.11.039_bib95","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib96","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.11.039_bib97","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/21645515.2015.1108500","article-title":"Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer","volume":"12","author":"Luckett","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2019.11.039_bib98","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.vaccine.2011.01.001","article-title":"HPV16\/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection","volume":"29","author":"Kemp","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib99","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.canlet.2019.11.039_bib100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/aje\/kwu168","article-title":"Rica Vaccine Trial, Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates","volume":"180","author":"Lang Kuhs","year":"2014","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canlet.2019.11.039_bib101","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J. Nat. Cancer. Inst."},{"key":"10.1016\/j.canlet.2019.11.039_bib102","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vaccine.2017.11.034","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14years: results to month 36 from a randomized trial","volume":"36","author":"Leung","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7584","article-title":"Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model","volume":"350","author":"Jit","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2019.11.039_bib104","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Electronic address, Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib105","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2019.11.039_bib106","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 Years versus a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.canlet.2019.11.039_bib107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2019.11.039_bib108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib109","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib111","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1111\/bcp.13736","article-title":"Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017","volume":"84","author":"Suragh","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2019.11.039_bib112","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.7490","article-title":"Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA","volume":"7","author":"Jia","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.canlet.2019.11.039_bib113","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14740338.2019.1598969","article-title":"Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy","volume":"18","author":"Scavone","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.canlet.2019.11.039_bib114","doi-asserted-by":"crossref","first-page":"1800380","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800380","article-title":"A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women","volume":"24","author":"Ward","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.canlet.2019.11.039_bib115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.31557\/APJCP.2019.20.3.869","article-title":"Post marketing surveillance study of 2nd dose quadrivalent human papilloma virus vaccine in elementary school children in Jakarta, Indonesia: safety result and implementation of school-based HPV immunization program","volume":"20","author":"Satari","year":"2019","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.canlet.2019.11.039_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231582","article-title":"Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination","volume":"12","author":"Pereira","year":"2019","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.canlet.2019.11.039_bib117","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12883-018-1233-y","article-title":"Myasthenia gravis following human papillomavirus vaccination: a case report","volume":"18","author":"Chung","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.canlet.2019.11.039_bib118","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/medicina54040050","article-title":"Human papilloma virus (HPV) and fertilization: a mini review","volume":"54","author":"Zacharis","year":"2018","journal-title":"Medicina"},{"key":"10.1016\/j.canlet.2019.11.039_bib119","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1080\/21645515.2016.1160178","article-title":"Is HPV vaccination in pregnancy safe?","volume":"12","author":"Bonde","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2019.11.039_bib120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/AOG.0000000000002694","article-title":"Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy","volume":"132","author":"Kharbanda","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.canlet.2019.11.039_bib121","series-title":"Pregnancy Outcomes after Human Papillomavirus Vaccination in Periconceptional Period or during Pregnancy: A Systematic Review and Meta-Analysis","first-page":"1","author":"Wang","year":"2019"},{"key":"10.1016\/j.canlet.2019.11.039_bib122","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1016\/j.vaccine.2018.08.071","article-title":"Evaluation of a 9-valent HPV vaccine in Sprague-Dawley rats: nonclinical studies assessing general, reproductive, and developmental toxicity","volume":"36","author":"Wise","year":"2018","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.canlet.2019.11.039_bib123","article-title":"Chapter 2: the burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib124","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejpb.2015.05.009","article-title":"Development of a highly thermostable, adjuvanted human papillomavirus vaccine","volume":"94","author":"Hassett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.canlet.2019.11.039_bib125","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(14)70481-4","article-title":"Present status of human papillomavirus vaccine development and implementation","volume":"16","author":"Herrero","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2019.11.039_bib127","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"Wang","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib128","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1128\/JVI.02726-07","article-title":"Arrangement of L2 within the papillomavirus capsid","volume":"82","author":"Buck","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib130","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2013.07.052","article-title":"A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants","volume":"31","author":"Tumban","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib131","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1016\/j.vaccine.2017.07.086","article-title":"Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes","volume":"35","author":"Kalnin","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib132","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4161\/hv.5.1.6554","article-title":"Development of an HPV vaccine for a broad spectrum of high-risk types","volume":"5","author":"Kanda","year":"2009","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169533","article-title":"Chimeric L2-based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV)","volume":"12","author":"Huber","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.11.039_bib134","article-title":"Identification of broad-genotype HPV L2 neutralization site for pan-HPV vaccine development by a cross-neutralizing antibody","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.11.039_bib135","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0264-410X(00)00354-6","article-title":"Use of live bacterial vaccine vectors for antigen delivery: potential and limitations","volume":"19","author":"Medina","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors--friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology (Read.)"},{"key":"10.1016\/j.canlet.2019.11.039_bib137","first-page":"10","article-title":"Live attenuated bacteria as vectors to deliver plasmid DNA vaccines","volume":"5","author":"Dietrich","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib138","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijmm.2007.09.002","article-title":"Listeria monocytogenes as novel carrier system for the development of live vaccines","volume":"298","author":"Schoen","year":"2008","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.canlet.2019.11.039_bib139","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/B978-0-12-394590-7.00004-X","article-title":"Listeria monocytogenes and its products as agents for cancer immunotherapy","volume":"113","author":"Guirnalda","year":"2012","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib140","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.micinf.2007.05.005","article-title":"Listeriolysin O: a phagosome-specific lysin","volume":"9","author":"Schnupf","year":"2007","journal-title":"Microb. Infect."},{"key":"10.1016\/j.canlet.2019.11.039_bib141","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ni1088","article-title":"The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules","volume":"5","author":"Watts","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib142","doi-asserted-by":"crossref","first-page":"542851","DOI":"10.1155\/2012\/542851","article-title":"Lm-LLO-based immunotherapies and HPV-associated disease","volume":"2012","author":"Wallecha","year":"2012","journal-title":"J. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib143","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib144","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5610","article-title":"ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer","volume":"32","author":"Basu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib145","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","article-title":"Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients","volume":"32","author":"Kawana","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib146","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1016\/j.vaccine.2018.05.009","article-title":"Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNgamma-producing cells","volume":"36","author":"Komatsu","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib147","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/vim.2005.18.283","article-title":"Adenoviral vectors for mucosal vaccination against infectious diseases","volume":"18","author":"Santosuosso","year":"2005","journal-title":"Viral Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib148","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mt.6300031","article-title":"Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib149","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.virol.2006.08.041","article-title":"Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells","volume":"358","author":"Hartman","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib151","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2013.228","article-title":"Circumventing antivector immunity: potential use of nonhuman adenoviral vectors","volume":"25","author":"Lopez-Gordo","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib152","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijc.30679","article-title":"Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease","volume":"141","author":"Khan","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib153","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/ijc.31166","article-title":"Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins","volume":"142","author":"Cuburu","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib154","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib156","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib157","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib158","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2019.11.039_bib159","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J. Gynecol Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib160","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.canlet.2019.11.039_bib161","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib162","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.6.2.227","article-title":"Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells","volume":"6","author":"Tsen","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.canlet.2019.11.039_bib163","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2019.11.039_bib164","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.11.039_bib165","first-page":"10","article-title":"RNA viruses as tools in gene therapy and vaccine development","author":"Lundstrom","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.canlet.2019.11.039_bib166","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science (N.Y.)"},{"key":"10.1016\/j.canlet.2019.11.039_bib167","first-page":"23","article-title":"Self-replicating RNA viruses for RNA therapeutics","author":"Lundstrom","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2019.11.039_bib168","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/vaccines4040039","article-title":"Replicon RNA viral vectors as vaccines","volume":"4","author":"Lundstrom","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.canlet.2019.11.039_bib169","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/JVI.74.9.4394-4403.2000","article-title":"Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors","volume":"74","author":"Varnavski","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.2008.00622.x","article-title":"Antigen-specific immunotherapy of cervical and ovarian cancer","volume":"222","author":"Hung","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2019.11.039_bib171","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/hum.2010.071","article-title":"Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents","volume":"22","author":"Zeng","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2019.11.039_bib172","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.vaccine.2011.11.002","article-title":"HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX((R)) B\/E","volume":"30","author":"Paris","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib173","doi-asserted-by":"crossref","first-page":"292951","DOI":"10.5402\/2011\/292951","article-title":"Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial","volume":"2011","author":"Solares","year":"2011","journal-title":"ISRN Obstet. Gynecol."},{"key":"10.1016\/j.canlet.2019.11.039_bib174","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nri1149","article-title":"Mhc-guided processing: binding of large antigen fragments","volume":"3","author":"Sercarz","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-016-1821-x","article-title":"Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination","volume":"65","author":"Coleman","year":"2016","journal-title":"Cancer Immunol. Immunother.(CII)"},{"key":"10.1016\/j.canlet.2019.11.039_bib176","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib177","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib178","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.039_bib179","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","article-title":"Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine","volume":"20","author":"de Jong","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib180","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","article-title":"Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7)","volume":"22","author":"Davidson","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2019.11.039_bib181","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2019.11.039_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib183","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.2174\/138161205774414565","article-title":"Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy","volume":"11","author":"Santin","year":"2005","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.canlet.2019.11.039_bib184","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/cei.12620","article-title":"The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-beta receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity","volume":"181","author":"Ahn","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2019.11.039_bib185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2008.12.006","article-title":"Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death","volume":"122","author":"Kim","year":"2009","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.canlet.2019.11.039_bib186","first-page":"265","article-title":"Cancer immunotherapy via dendritic cells, Nature reviews","volume":"12","author":"Palucka","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib187","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12967-014-0353-4","article-title":"Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer","volume":"12","author":"Rahma","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib188","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1200\/JCO.2014.60.6566","article-title":"Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer","volume":"33","author":"Zsiros","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib189","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovic","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib190","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.039_bib191","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CJI.0b013e318279652e","article-title":"Human papillomavirus type 16 E6\/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies","volume":"36","author":"Ramos","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2019.11.039_bib192","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","article-title":"Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy","volume":"30","author":"Cantelmo","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.11.039_bib193","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.canlet.2017.06.035","article-title":"Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery","volume":"403","author":"Kim","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.039_bib194","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3181\/00379727-32-7770P","article-title":"Carcinomatous changes in virus-induced papillomas of the skin of the rabbit","volume":"32","author":"Rous","year":"1935","journal-title":"PSEBM (Proc. Soc. Exp. Biol. Med.)"},{"key":"10.1016\/j.canlet.2019.11.039_bib195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.67.3.399","article-title":"The carcinogenic effect of a papilloma virus on the tarred skin of rabbits : I. Description of the phenomenon","volume":"67","author":"Rous","year":"1938","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2019.11.039_bib196","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ijc.2910130509","article-title":"Attempts to detect virus-secific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus","volume":"13","author":"zur Hausen","year":"1974","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib197","first-page":"794","article-title":"Condylomata acuminata and human genital cancer","volume":"36","author":"zur Hausen","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.039_bib198","first-page":"505","article-title":"Condylomatous lesions of the cervix and vagina. I. Cytologic patterns","volume":"20","author":"Meisels","year":"1976","journal-title":"Acta Cytol."},{"key":"10.1016\/j.canlet.2019.11.039_bib199","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","article-title":"A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions","volume":"80","author":"Durst","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.11.039_bib200","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/j.1460-2075.1984.tb01944.x","article-title":"A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer","volume":"3","author":"Boshart","year":"1984","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2019.11.039_bib201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/314111a0","article-title":"Structure and transcription of human papillomavirus sequences in cervical carcinoma cells","volume":"314","author":"Schwarz","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.039_bib202","first-page":"361","article-title":"Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines","volume":"119","author":"Yee","year":"1985","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2019.11.039_bib203","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53","volume":"248","author":"Werness","year":"1990","journal-title":"Science (N.Y.)"},{"key":"10.1016\/j.canlet.2019.11.039_bib204","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1128\/jvi.66.12.6893-6902.1992","article-title":"Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins","volume":"66","author":"Dyson","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2019.11.039_bib205","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ijc.2910510527","article-title":"Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA","volume":"51","author":"von Knebel Doeberitz","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.11.039_bib206","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(87)91072-5","article-title":"Human papillomavirus infections in women with and without abnormal cervical cytology","volume":"2","author":"de Villiers","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.11.039_bib207","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2019.11.039_bib208","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/21801","article-title":"Genetic link to cervical tumours","volume":"400","author":"Magnusson","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.039_bib209","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J. Nat. Cancer. Inst."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:46:39Z","timestamp":1759592799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519306044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":207,"alternative-id":["S0304383519306044"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.11.039","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccine against cervical cancer: Opportunity and challenge","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}